Clinical trial
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant…
NCT00373425 · OSI Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00373425 |
|---|---|
| Title | A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors |
| Official title | A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors |
| Acronym | RADIANT |
| Lead sponsor | OSI Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib, Placebo |
| Enrollment | 1,252 |
| Start date | Sep 1, 2006 |
| Primary completion | Apr 1, 2013 |
| Completion | Jun 1, 2014 |
| First posted | Sep 8, 2006 |
| Last update posted | Sep 17, 2015 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Italy, Poland and 7 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: